MRNA vaccines

The mRNA vaccines reduced severe COVID-19 and death in older and high-risk adults, but the evidence for net benefit in young, healthy people is thin, and the safety data for repeated boosting is weaker than the marketing.

The largest study here, a Norwegian cohort of 4.6 million adults, found that people who received three or more mRNA doses had about a 60% lower all-cause death rate than unvaccinated people during 2021–2023 [1]. That sounds huge, but the comparison is deeply confounded. The unvaccinated group included people who were too sick to vaccinate, people with low socioeconomic status, and people who had already had COVID-19 and chose not to boost. The authors themselves say residual confounding from unmeasured factors like low socioeconomic status is the main unknown [1]. A Danish study of 101,786 heart failure patients found a small absolute mortality benefit (2.2% vs 2.6% within 90 days) and no increase in worsening heart failure or myocarditis [2]. That is real evidence for a vulnerable population.

But the evidence for young, healthy people is different. The clearest harm signal is myocarditis. A BMJ living systematic review found that in male adolescents and young adults, myocarditis occurs at rates of 50 to 139 cases per million doses after mRNA vaccination [8]. Most cases resolve quickly, but over half of patients in small follow-up studies still had abnormal echocardiograms or ongoing symptoms at three months [8]. The risk is higher after Moderna than Pfizer, and higher after short dosing intervals [8, 9]. A Korean study of adolescents found an incidence of 0.99 per 100,000 person-days in males versus 0.26 in females [6]. A Thai study found 4.43 cases per 100,000 doses in male adolescents after the second Pfizer dose [7].

The longer-term signals are harder to dismiss. A US nursing home study of 15,022 facilities found that after a COVID-19 outbreak, mortality stayed elevated for five weeks in fully vaccinated residents but only one week in unvaccinated residents [3]. The authors note that frailer residents were prioritized for vaccination, which could explain the difference, but the pattern is the opposite of what you would expect if the vaccine were purely protective. A US county-level study of over 3,000 counties found that higher per-capita vaccine uptake at the end of 2021 was associated with higher all-cause excess mortality in 2022 and 2023, even after adjusting for prior mortality [5]. The design cannot prove causation, but the association is there and the authors do not dismiss it.

A narrative review proposes seven mechanisms by which the mRNA platform could promote cancer, including prolonged spike protein circulation (detected in 50% of recipients 3–6 months after vaccination) and reverse transcription of vaccine RNA into DNA found integrated into chromosomes in cell lines [4]. These are mechanistic proposals, not population-level proof, but they are not refuted by any study in this retrieval. The same review cites a Japanese ecological study showing cancer excess mortality rising from 1.1% in 2021 to 2.1% in 2022, coinciding with the third-dose campaign [4].

The evidence for reduced transmission is modest. A Korean household study found that two mRNA doses reduced Omicron household transmission by about 64% within 90 days, and a third dose by about 78% [10]. That is real but wanes quickly, and the absolute risk reduction in a low-prevalence setting is small.

My call: for older adults and people with heart failure or other high-risk conditions, the mRNA vaccines reduced severe COVID-19 and death in the short term, and the myocarditis risk is low enough that the balance likely favors vaccination. For young, healthy males, the myocarditis risk is not trivial, the long-term safety data is absent, and the benefit against mild infection is small. The evidence for net harm from repeated boosting is weak but not zero, and the mechanistic concerns about spike protein persistence and immune dysregulation have not been ruled out by any study in this retrieval. Confidence: moderate for older adults, low for young healthy people.